Avedro, Inc. Announces Completion of 1st US Phase III Corneal Cross-linking Clinical Trials

WALTHAM, Mass.--(BUSINESS WIRE)--Avedro, Inc. today announced the completion of all one-year follow-up visits for patients enrolled in its two multi-center Phase III studies evaluating the safety and efficacy of corneal collagen cross-linking for the treatment of progressive keratoconus and ectasia following refractive surgery.

MORE ON THIS TOPIC